February 2005
Medical Marketing & Media;Feb2005, Vol. 40 Issue 2, p12
Trade Publication
The article presents news from the pharmaceutical industry. Pfizer Inc. received a setback when the FDA classified its newly approved nerve pain drug Lyrica as a controlled substance, resulting in additional requirements for doctors and pharmacists. Pfizer had been counting on Lyrica to offset declines in sales for Neurontin, whose patent expired last year. The FDA approved Macugen 0.3 mg, for the treatment of neovascular age-related macular degeneration. It will be co-marketed by Eyetech Pharmaceuticals Inc. and Pfizer.


Related Articles

  • FDA Approves Eyetech/Pfizers Macugen.  // Review of Ophthalmology;Jan2005, Vol. 12 Issue 1, p4 

    The article reports that the U.S. food and Drug Administration has approved Macugen injection for the treatment of neovascular age-related macular degeneration. The injection has been developed by Eyetech Pharmaceuticals Inc. and Pfizer Inc. Macugen is the first in a new class of ophthalmic...

  • Priority review for Pfizer, Eyetech AMD drug.  // PharmaWatch: Biotechnology;October 2004, Vol. 3 Issue 10, p11 

    The article reports that Macugen, a treatment for age-related macular degeneration jointly developed by Pfizer Corp. and Eyetech Pharmaceuticals Inc. has been granted a priority review designation by the U.S.Food and Drug Administration (FDA). The companies submitted the final portion of the new...

  • New Eye Drug Approved. Mirasol, Feliza // Chemical Market Reporter;1/10/2005, Vol. 267 Issue 2, p10 

    Reports on the approval of the U.S. Food and Drug Administration to new eye drug Macugen of Eyetech Pharmaceuticals Inc. and co-developer Pfizer Inc. Use of Macugen in the treatment of neovascular age-related macular degeneration; Price of the drug; Development of Macugen.

  • Pegaptanib sodium injection available for treatment of AMD-related CNV. Guttman, Cheryl // Ophthalmology Times;1/15/2005, Vol. 30 Issue 2, p1 

    This article reports that the FDA approved pegaptanib sodium injection by Macugen, Eyetech Pharmaceuticals and Pfizer Ophthalmics for the treatment of neovascular age-related macular degeneration (AMD) on December 17. With the regulatory agency's decision, pegaptanib sodium became the first...

  • Pfizer's Lyrica receives FDA approval.  // PharmaWatch: CNS;Aug2007, Vol. 6 Issue 8, p18 

    The article reports on the drug approval released by the U.S. Food and Drug Administration to Pfizer Inc. for its Lyrica capsules. The drug is designed for the management of fibromyalgia which is considered as the most common chronic, widespread pain condition in the U.S. The company states that...

  • New Drug Treats Age-Related Macular Degeneration.  // FDA Consumer;Mar/Apr2005, Vol. 39 Issue 2, p4 

    Announces the approval given by the U.S. Food and Drug Administration to the drug Macugen from Eyetech Pharmaceuticals Inc. and Pfizer Inc. to slow vision loss in people with wet age-related macular degeneration (AMD). Overview of the therapeutic application of the drug targeting vascular...

  • Eyetech aims to be retina specialists' biotech resource. Dlugoss, Mark L. // Ophthalmology Times;6/1/2005, Vol. 30 Issue 11, p3 

    Reports on the projects being explored by New York-based Eyetech Pharmaceuticals to deliver medical solutions for the betterment of patients who suffer from blinding eye diseases. Implication of the U.S. Food and Drug Administration's approval of Eyetech's pegaptanib sodium injection product for...

  • Letters to the Editor. Crary, Ely J.; Tseng, Scheffer C. G. // Ophthalmology Times;10/15/2004, Vol. 29 Issue 20, p6 

    Presents several letters to the editor. Role of nutrition in the prevention of age-related macular degeneration; Pharmaceutical companies developing amniotic membranes; Drug approval for amniotic membrane, granted by the U.S. Food and Drug Administration.

  • New cholesterol products carry high stakes for drugmakers. Wolinsky, Howard // Modern Healthcare;4/13/2015, Vol. 45 Issue 15, p0028 

    The article offers information on drugmakers across the U.S. that are focusing on making new cholesterol products after the approval of the PCSK9 inhibitors, known for lowering cholesterol level, by the Food and Drug Administration (FDA). Topics discussed include Paris, France-based Sanofi is...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics